Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology, Basic and Translational - Early Phase (Phase 0 or I) human studies

Fibroblast activation protein-targeted radionuclide therapy of solid tumors using [177Lu]Lu-DOTAGA-Glu-(FAPi)2: biodistribution and dosimetry

Jens Kurth, Bernd Krause, Helena Lanzafame, Markus Joksch, Wolfgang Fendler, Ken Herrmann, Frank Rösch and Martin Heuschkel
Journal of Nuclear Medicine June 2024, 65 (supplement 2) 242022;
Jens Kurth
1Rostock University Medical Center, Rostock, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernd Krause
1Rostock University Medical Center, Rostock, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helena Lanzafame
2Department of Nuclear Medicine, University Hospital Essen, Essen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Joksch
3Rostock University Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang Fendler
4University Hospital Essen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken Herrmann
2Department of Nuclear Medicine, University Hospital Essen, Essen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Rösch
5Johannes Gutenberg University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Heuschkel
6Universitätsmedizin Rostock
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 65 no. supplement 2 242022

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online June 9, 2024.

Copyright & Usage 
© 2024

Author Information

  1. Jens Kurth1,
  2. Bernd Krause1,
  3. Helena Lanzafame2,
  4. Markus Joksch3,
  5. Wolfgang Fendler4,
  6. Ken Herrmann2,
  7. Frank Rösch5 and
  8. Martin Heuschkel6
  1. 1Rostock University Medical Center, Rostock, Germany
  2. 2Department of Nuclear Medicine, University Hospital Essen, Essen, Germany
  3. 3Rostock University Medical Center
  4. 4University Hospital Essen
  5. 5Johannes Gutenberg University
  6. 6Universitätsmedizin Rostock

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: June 2024 to April 2025

AbstractFullPdf
Jun 20249300
Jul 202419300
Aug 202415200
Sep 202413000
Oct 202414400
Nov 202413400
Dec 20249400
Jan 202511100
Feb 202511600
Mar 20257700
Apr 20258700
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 65, Issue supplement 2
June 1, 2024
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Fibroblast activation protein-targeted radionuclide therapy of solid tumors using [177Lu]Lu-DOTAGA-Glu-(FAPi)2: biodistribution and dosimetry
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Fibroblast activation protein-targeted radionuclide therapy of solid tumors using [177Lu]Lu-DOTAGA-Glu-(FAPi)2: biodistribution and dosimetry
Jens Kurth, Bernd Krause, Helena Lanzafame, Markus Joksch, Wolfgang Fendler, Ken Herrmann, Frank Rösch, Martin Heuschkel
Journal of Nuclear Medicine Jun 2024, 65 (supplement 2) 242022;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Fibroblast activation protein-targeted radionuclide therapy of solid tumors using [177Lu]Lu-DOTAGA-Glu-(FAPi)2: biodistribution and dosimetry
Jens Kurth, Bernd Krause, Helena Lanzafame, Markus Joksch, Wolfgang Fendler, Ken Herrmann, Frank Rösch, Martin Heuschkel
Journal of Nuclear Medicine Jun 2024, 65 (supplement 2) 242022;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Al18F-NOTA-HER2-BCH affibody PET imaging accurately map HER2 positive lesions of breast cancer
  • Molecular imaging of acute radiation-induced esophagitis using [18F]AlF labeled polypeptide targeting C-X-C-chemokine-receptor-type-4
  • A Phase I/IIa of [212Pb]VMT--NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
Show more Oncology, Basic and Translational - Early Phase (Phase 0 or I) human studies

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire